Blue Note Therapeutics
7
0
0
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
57.1%
4 terminated/withdrawn out of 7 trials
20.0%
-66.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Psychological Mobile App for Patients With AML
Role: collaborator
Cognitive-Behavioral Stress Management Device for the Treatment of Anxiety and Depressive Symptoms in Patients With Stage I-III Breast or Lung Cancer
Role: collaborator
Long-term Follow-up of RESTORE Study
Role: lead
Virtual Trial to Compare Two Digital Therapeutics as Interventions for Physical and Mental Health in People With Cancer
Role: lead
BNT001 Digital Therapeutic Feasibility Pilot Study
Role: lead
Blue Note Therapeutics Product BNT 103 Usability and User Engagement
Role: lead
Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices as Adjunctive Oncology Treatment
Role: lead
All 7 trials loaded